Your browser doesn't support javascript.
loading
Incidence of Elevated Liver Enzyme Levels in Patients Receiving Remdesivir and Its Effective Factors.
Seyedalipour, Fatere; Alipour, Shabnam; Mehdinezhad, Hamed; Akrami, Rahim; Shirafkan, Hoda.
Afiliación
  • Seyedalipour F; Clinical Research Development Unit of Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran.
  • Alipour S; Faculty of Pharmacy, Ayatollah Amoli branch, Islamic Azad University, Amol, Iran.
  • Mehdinezhad H; Department of Internal Medicine, Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran.
  • Akrami R; School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Shirafkan H; Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Middle East J Dig Dis ; 16(2): 109-113, 2024 Apr.
Article en En | MEDLINE | ID: mdl-39131106
ABSTRACT

Background:

Emergency use of remdesivir was approved for COVID-19 in some countries. Based on the promising results of remdesivir, the most common side effects were nausea, worsening respiratory failure, increased alanine aminotransferase levels, and constipation. The aim of this study was to determine the incidence of elevated liver enzymes in patients with COVID-19 receiving remdesivir.

Methods:

In this retrospective study, information was collected from patients' files. The study population included patients with moderate to severe COVID-19 who were admitted to Rouhani Babol Hospital. For daily patient selection, the list of patients was extracted from the system, and based on the census, the patient file was selected. Data were analyzed using Stata 16.

Results:

620 patients suffering from moderate to severe COVID-19 were included in this study, 43% of whom were men. Of these patients, 120 were selected as the control group who did not receive remdesivir. The increase in liver enzymes in patients receiving remdesivir compared with the control, for alanine transaminase (ALT) and aspartate transaminase (AST), respectively, was 6.20 and 3.64 times, but it was not statistically significant for alkaline phosphatase (ALP). Also, the increase in bilirubin levels in patients receiving remdesivir was not statistically significant.

Conclusion:

The recipients of remdesivir had high liver enzymes, which is one of the possible side effects of this drug. The intensity of the enzymes was mild and moderate, and they were not dangerous to the health of any of the consumers. Deaths in patients with COVID-19 were not due to drug-induced liver complications but to other factors such as disease-related complications.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Middle East J Dig Dis Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Middle East J Dig Dis Año: 2024 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Irán